NDA 022318 · Genzyme
Renvela
Sevelamer Carbonate · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Apr 30, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Aug 12, 2009
Approved uses
2
Original approval plus efficacy supplements
Registered trials
60
23 Phase 3, 1 recruiting
FAERS reports
11,505
5,643 serious, 1,228 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 25, 2025.
Sevelamer carbonate is indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease (CKD) on dialysis. Sevelamer carbonate is a phosphate binder indicated for the control of serum phosphorus in adults and children 6 years of age and older with chronic kidney disease on dialysis. ( 1 )
Mechanism: Sevelamer carbonate is a non-absorbed phosphate-binding cross-linked polymer, free of metal and calcium. It contains multiple amines separated by one carbon from the polymer backbone. These amines exist in a protonated form in the intestine and interact with phosphate molecules through ionic and hydrogen bonding. By binding phosphate in the gastrointestinal tract and decreasing absorption, sevelamer carbonate lowers the phosphate concentration in the serum (serum phosphorus).
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 25, 2016 Supplement 8 · Efficacy · priority review LetterLabel
- Aug 12, 2009 Original approval · Type 3 - New Dosage Form LabelLetterReview
2 products under this application
- RENVELA · SEVELAMER CARBONATE 2.4GM/PACKET · FOR SUSPENSION, ORAL · Discontinued · TE AB
- RENVELA · SEVELAMER CARBONATE 800MG/PACKET · FOR SUSPENSION, ORAL · Discontinued · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Sevelamer Carbonate" as an intervention, any sponsor and status, largest first.
- A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on DialysisPivotal-lookingCompleted
ArdelyxIndustry
NCT03427125 · 1,559 participants · Start Jan 8, 2018 · Primary completion Nov 15, 2019
Drug: Tenapanor; Placebo and 1 more · For: Hyperphosphatemia
Sites: The Bronx, New York; Winston-Salem, North Carolina
- A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis PatientsPivotal-lookingCompleted
Vifor PharmaIndustry
NCT01324128 · 1,059 participants · Start Mar 2011 · Primary completion Apr 2012
Drug: PA21 (2.5 g tablet containing 500 mg iron); Sevelamer carbonate and 1 more · For: Chronic Kidney Disease Requiring Chronic Dialysis
Sites: San Antonio, Texas; Sankt Pölten, Austria; Liège, Belgium · 15 sites in all
- A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis PatientsPivotal-lookingCompleted
Vifor PharmaIndustry
NCT01464190 · 659 participants · Start Sep 2011 · Primary completion Oct 2012
Drug: PA21 (2.5 g tablet containing 500 mg iron); Sevelamer carbonate · For: Chronic Kidney Disease Requiring Chronic Dialysis
Sites: San Antonio, Texas; Sankt Pölten, Austria; Liège, Belgium · 15 sites in all
- AP301 Efficacy and Safety in Chinese Dialysis Patients With HyperphosphatemiaPivotal-lookingCompleted
Alebund PharmaceuticalsIndustry
NCT07030595 · 474 participants · Start Jun 12, 2023 · Primary completion Oct 2, 2024
Drug: AP301; Sevelamer carbonate (Renvela®) and 1 more · For: ESRD (End Stage Renal Disease); Chronic Kidney Disease(CKD); Hyperphosphatemia and 3 more
Sites: Beijing, China; Jilin City, China; Xiamen, China · 50 sites in all
- A 58-Week Safety and Efficacy Trial of Ferric Citrate in Patients With ESRD on DialysisPivotal-lookingCompleted
Keryx BiopharmaceuticalsIndustry
NCT01191255 · 441 participants · Start Oct 2010 · Primary completion Jan 2013
Drug: ferric citrate, ca acetate, sevelamer carbonate, placebo · For: Hyperphosphatemia; Kidney Failure
Sites: Tempe, Arizona; Los Angeles, California; Riverside, California · 56 sites in all
- Reduce Cardiovascular Calcifications to Reduce QT Interval in DialysisPivotal-lookingCompleted
Azienda Sanitaria ASL Avellino 2Academic, hospital or other
NCT00710788 · 360 participants · Start Jan 2007 · Primary completion Sep 2010
Drug: sevelamer phosphate-binders; Calcium Carbonate · For: Cardiovascular Mortality
Sites: Solofra, Italy
- Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on HemodialysisPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT00853242 · 349 participants · Start Feb 2009 · Primary completion Aug 2009
Drug: Placebo; Genz-644470 and 1 more · For: Kidney Failure, Chronic
Sites: Alexander City, Alabama; Birmingham, Alabama; Hot Springs, Arkansas · 53 sites in all
- PA21 Safety and Efficacy in Adult Chinese SubjectsPivotal-lookingCompleted
Vifor Fresenius Medical Care Renal PharmaIndustry
NCT03644264 · 286 participants · Start Aug 31, 2018 · Primary completion Aug 21, 2020
Drug: PA21; sevelamer carbonate · For: Chronic Kidney Disease Requiring Chronic Dialysis; Hyperphosphatemia
Sites: Guangzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- constipation2,548
- diarrhoea1,057
- pruritus1,009
- nausea819
- chronic kidney disease676
- end stage renal disease674
- renal failure666
- death628
- vomiting533
- acute kidney injury515
- abdominal pain308
- nephrogenic anaemia298
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2008 | 4 |
| 2009 | 54 |
| 2010 | 74 |
| 2011 | 165 |
| 2012 | 239 |
| 2013 | 1,071 |
| 2014 | 3,605 |
| 2015 | 890 |
| 2016 | 678 |
| 2017 | 875 |
| 2018 | 824 |
| 2019 | 790 |
| 2020 | 487 |
| 2021 | 368 |
| 2022 | 277 |
| 2023 | 262 |
| 2024 | 273 |
| 2025 | 355 |
| 2026 | 214 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Renvela (Sevelamer Carbonate)
2024 spending
$38.0M
Beneficiaries
8,189
27,433 claims
Per beneficiary
$4,639
$6.39 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $296,303,290 |
| 2021 | $193,692,542 |
| 2022 | $144,276,421 |
| 2023 | $114,323,301 |
| 2024 | $37,991,213 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of sucroferric oxyhydroxide versus sevelamer carbonate: A systematic review and meta-analysis.
Georgopoulos C, Duni A, Stamellou E, et al. · Hemodial Int 2025 · Systematic Review, Meta-Analysis
- Iron-related parameters in dialysis patients treated with sucroferric oxyhydroxide.
Covic AC, Floege J, Ketteler M, et al. · Nephrol Dial Transplant 2017 · Clinical Trial, Phase III, Randomized Controlled Trial
- Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients.
Floege J, Covic AC, Ketteler M, et al. · Nephrol Dial Transplant 2015 · Clinical Trial, Phase III, Randomized Controlled Trial
- Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients.
Sprague SM, Ketteler M, Covic AC, et al. · Hemodial Int 2018 · Multicenter Study, Randomized Controlled Trial
- The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis.
Habbous S, Przech S, Acedillo R, et al. · Nephrol Dial Transplant 2017 · Comparative Study, Meta-Analysis
- Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease.
Ginsberg C, Zelnick LR, Block GA, et al. · Nephrol Dial Transplant 2020 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
Sponsor: Sanofi
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.